Bloom Health Partners Announces New Location in Hawaii

New Bloom lab will support operations in the Honolulu area and surrounding region

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces the opening of a new location in in the Honolulu area.

The new location provides expanded laboratories for operational health services and diagnostic testing to meet continued demand. Bloom has also added a local team. The Honolulu location will serve film/TV productions in addition to new opportunities with local businesses and organizations in the surrounding area.

"Adding services in Honolulu shows flexibility in our business model," said Andrew Morton, CEO of Bloom. "We've shown the local market in the Hawaiian islands our willingness to bring services directly to them. The clients that brought us to Hawaii are a great baseline for Bloom to prove out a longer term model of support for health services across the United States. We continue to be focused on delivering technology enabled, operational health services to large employers."

The Company also announces that in connection with closing the second tranche of its previously announced non-brokered private placement offering (the "Offering") on July 18, 2022, total compensation paid was C$33,240 and 166,200 compensation options, and not as previously indicated. All securities issued in connection with the Offering are subject to a statutory hold period until November 19, 2022 in accordance with applicable securities laws.

About Bloom Health Partners Inc.
Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) is a global platform for healthcare security, diagnostic testing and occupational health-tech. Our mission is to ensure that "unstoppable is possible" for businesses and their employees through innovative, customized healthcare models. Bloom offers a system for businesses and organizations that helps engage employees and creates strategies to manage health and safety. Our stable, scalable system is an integrated health-tech platform that securely manages data while delivering comprehensive workplace health and safety outcomes.

For more information: info@bloomhealthpartners.com

On behalf of the board of directors,

Bloom Health Partners Inc.

Andrew Morton, Chief Executive Officer

Forward-Looking Statements

This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in the Company's forward-looking statements include the potential that milestones may not be satisfied, acquisitions may not achieve expected benefits, financing requirements, and the other risk factors described in the Company's filings with Canadian securities regulators on www.sedar.com. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/137059

News Provided by Newsfile via QuoteMedia

Bloom Health Partners CSE: BLMH Emerging Tech Investing

BLMH:CNX

Bloom Health Partners Announces Leadership Transition

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of diagnostic and health technology services, announces a leadership transition.

Effective September 30, 2022, Andrew Morton has stepped down as CEO of the Company to pursue other opportunities. Rosemary Elliston, COO of the Company, has been appointed to the position of Interim CEO. Mr. Morton will continue to support the Company as a Director.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Bloom Health Partners CEO to Speak at Health Benefits Nation Conference in Orlando

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces its CEO, Andrew Morton, will speak on a panel at Health Benefits Nation Conference in Orlando, Florida on September 15th, 2022.

Mr. Morton will join co-panelists Eric Hargan, former U.S. Federal Deputy Secretary of the Department of Health and Human Services (DHHS), and Jeff Hogan, President of Upside Health Advisors. The panel titled "Incorporating Occupational Health into Value Based Health Strategies" will focus on workplace health and using data models to improve outcomes in occupational health in such areas as preventive care and mental health.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Bloom Health Partners Announces Closing of Second Tranche of Private Placement for over C$1.58M in Aggregate Gross Proceeds

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces that it has closed the second tranche of its previously announced non-brokered private placement offering (the "Offering") and has issued 2,770,000 units (the "Units") at $0.20 per Unit for gross proceeds of C$554,000. Combined with the first tranche of the Offering, the Company has sold 7,920,000 Units of the Company for aggregate gross proceeds of C$1,584,000. The Units are comprised of (i) one (1) common share in the capital of the Company ("Common Shares"); and (ii) one-half (12) of a transferable common share purchase warrant (each whole warrant, a "Warrant" and collectively, the "Warrants"). Each Warrant entitles the holder thereof to acquire one (1) additional Common Share (each, a "Warrant Share") in the capital of the Company at a price of $0.30 per Warrant Share until July 18, 2023. The net proceeds of the Offering will be used by the Company for ongoing working capital and corporate development.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Syntheia Set to Enhance Customer Communication with Its AI-Powered Virtual Assistant

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, a Canadian leader in conversational AI, announces that its innovative SaaS platform, designed to transform how businesses manage inbound telephone calls is set to launch in January of 2025. Leveraging advanced Natural Language Processing (NLP), Syntheia's virtual assistants enhance communication and efficiency targeting small and medium businesses in this large global marketplace.

" Our mission is to eliminate as many inefficiencies as we can with managing inbound calls that small to medium-sized businesses face utilizing the power of AI" said Tony Di Benedetto, CEO of Syntheia. "With AI-driven virtual assistants, we provide these businesses with tools to improve customer satisfaction while reducing operational costs. We are gearing up now for commercial launch in January of 2025, less than 8 weeks away."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that its Chief Scientific Officer, Dr. Len Pagliaro, has been invited to showcase Sona's developing Targeted Hyperthermia Therapy ("THT") cancer treatment today at the Nanotechnology Characterization Laboratory ("NCL"). Sona will be one of six commercial and academic collaborators to present its research at the NCL's 20th anniversary "Advancing Medical Applications of Cancer Nanotechnology" symposium. Sona's subsidiary was previously selected for the NCL Assay Cascade Program, the premier program in the World for bringing nanomaterials through critical preclinical stages and facilitating regulatory review, in which Sona's materials were assessed for biocompatibility. The NCL was established by the National Cancer Institute ("NCI") to accelerate the progress of nanomedicine by providing preclinical characterization and safety testing of nanoparticles. The NCL is a collaborative effort between NCI, the U.S. Food and Drug Administration ("FDA"), and the National Institute of Standards and Technology.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Sona Nanotech Issued Patent and Appoints New Board Member

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce the issuance of U.S. Patent No. 12117447 by the U.S. Patent and Trademark Office to the Company, entitled, "Metal Nanoparticles and Methods of Making Same". This patent covers the Company's proprietary process for manufacturing gold nanorods without the use of the toxic substance, cetyltrimethylammonium bromide ("CTAB"), which typically carries significant cytotoxic and genotoxic risks.

The Company is also pleased to announce the appointment of Mr. Wayne Myles, KC, FIIC, to its board of directors. An active investor and entrepreneur, Mr. Myles has served as lead counsel and strategic business advisor on more than 100 domestic and international acquisitions and sales, financings, government and regulatory affairs and licensing mandates. He has significant and diverse experience as a director of public and private companies. He also has been recognized with numerous professional achievements, distinctions and awards, including being named as one of "Canada's Top 25 Most Influential Lawyers' by Canadian Lawyer Magazine."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

		For the three months ended June 30
		2022			2021
Net income before tax	$	31,492		$	(1,065,599	)
Amortization of intangibles		706,453			-
Depreciation		120,095			-
Interest expense		391,181			-
EBITDA		1,249,221			(1,065,599	)
Debt modification gain		(130,033	)		-
Fair value loss on contingent consideration		274,642			-
Adjusted EBITDA	$	1,393,830		$	(1,065,599	)

Bloom Health Partners Announces New Location in Hawaii

Latest News

Latest Press Releases

Related News

TOP STOCKS